Retrouvez dans cette section l’ensemble
des publications du GERCOR répertoriées par année.
TUMEURS COLORECTALES
Contenus 2026 à venir
Cotte E, et al. Rectal cancer – French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR). Dig Liver Dis. 2025 Mar;57(3):669-679. doi: 10.1016/j.dld.2024.12.004. Epub 2024 Dec 17. PMID: 39694751
Taieb J, et al. Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials. J Clin Oncol. 2025 May;43(13):1564-1577. doi: 10.1200/JCO.24.00648. Epub 2025 Feb 4. PMID: 39903903
Depotte L, et al. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study. J Immunother Cancer. 2025 May 19;13(5):e011220. doi: 10.1136/jitc-2024-011220. PMID: 40389373
Parent P, et al. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13595. doi: 10.1002/jcsm.13595. Epub 2025 Jan 17. PMID: 39825571
Lefevre JH, et al. Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES). Dig Liver Dis. 2026 Jan;58(1):51-55. doi: 10.1016/j.dld.2025.11.003. Epub 2025 Nov 22. PMID: 41276451
Taieb J, et al. Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative. ESMO Open. 2025 May;10(5):105055. doi: 10.1016/j.esmoop.2025.105055. Epub 2025 May 6. PMID: 40334313
Gallois C, et al. Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials. J Clin Oncol. 2025 May 20;43(15):1765-1776. doi: 10.1200/JCO.23.02262. Epub 2025 Jan 31. PMID: 39889251
Vienot A, et al. Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials. Cancer Res Commun. 2025 Feb 1;5(2):287-294. doi: 10.1158/2767-9764.CRC-24-0246. PMID: 39807836
Pilati C, et al. ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts. Gastroenterology. 2025 Apr;168(4):714-724.e4. doi: 10.1053/j.gastro.2024.10.046. Epub 2024 Nov 28. PMID: 39612956
Delaye M, et al. Durvalumab plus tremelimumab after platinum failure in biliary tract cancer: IMMUNOBIL PRODIGE 57. Annals of Oncology (2025) 36 (suppl_2): S233-S244. 10.1016/annonc/annonc1902. Mini Oral session: 80MO. 2025 ESMO Congress
Cohen R, et al. Efficacy and safety of two schemes of nivolumab and ipilimumab in MSI/dMMR metastatic CRC: PRODIGE-74 GERCOR NIPISAFE phase II trial. ESMO 2025, Annals of Oncology (2025) 36 (suppl_2): S506-S599. 10.1016/annonc/annonc1915. Poster 812P.
Cohen R, et al. Nivolumab and ipilimumab in anti-PD1-resistant MSI/dMMR metastatic CRC: Interim analysis of GERCOR NIPIRESCUE phase II trial. ESMO 2025, Ann Oncol. 2025;36(suppl_2):S506-S599. DOI:10.1016/annonc/annonc1915. ePoster 879eP
Depotte L, et al. Nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: Final survival analysis and prognostic evaluation of GDF-15 in GERCOR NIPICOL phase II study. ESMO 2025, Abstract 544P. Ann Oncol. 2025;36(suppl_2):S506-S599. DOI:10.1016/annonc/annonc1915
Blanchet-Deverly S, et al. Biological and therapeutic impact of tumor mutational burden in MSI/dMMR metastatic CRC treated with ICIs. J Clin Oncol. 2025;43(4_suppl):272-272. Abstract 272, Poster Bd: L6. NIPICOL study. 2025 ASCO GI
Kempf E, et al. Acupuncture in oxaliplatin-induced peripheral neuropathy (NPIO) in patients with digestive tumors: Results of Cohort 2 of ACUPOX GERCOR G-114 Study. 38th ICMART 2025, Antibes, Abstract + Oral presentation
Kempf E, et al. Intérêt de l’acupuncture dans la neuropathie périphérique induite par l’oxaliplatine chez patients exposés à l’oxaliplatine: Analyse intermédiaire cohorte 2 (C2). JFHOD 2025, Abstract. Poster P424.
Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Ann Oncol. 2022;33(6):628-637.
Cohen R, Raeisi M, Chibaudel B, et al. Efficacy of immune checkpoint inhibitors for metastatic CRC with MSI in second or later line using synthetic control arms: NIPICOL. Eur J Cancer. 2024;199:113537.
Gandini A, Gallois C, Blons H, et al. Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients. Ann Oncol. 2024;35(Suppl 2):S428-S481. ESMO 2024, Abstract, Poster session 16.
Taieb J, Souglakos I, Boukovinas I, et al. Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: post hoc analysis of IDEA-France and -Greece trials. Ann Oncol. 2024;35(Suppl 1):S1-S74. ESMO 2024, Abstract 317MO, Mini Oral session: GI.
Borg C, Dourthe L, Andre T, et al. Angiopietin-2 (Ang-2) as a potential biomarker for guiding bevacizumab or anti-EGFR in RAS/BRAF wt unresectable mCRC: exploratory analysis of STRATEGIC-1. Ann Oncol. 2024;35(Suppl 1):S1-S74. ESMO GI 2024, Abstract; Poster 116P.
Depotte L, Nay P, Borg C, et al. Nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: Final survival analysis and prognostic evaluation of GDF-15 in GERCOR NIPICOL phase II study. Ann Oncol. 2024;35(Suppl 2):S428-S481. ESMO 2024, Abstract 544P; Poster.
Bachet JB, Bouché O, Trouilloud I, et al. G-CSF secondary prophylaxis with FTD/TPI in mCRC: LONGBOARD. Ann Oncol. 2024;ESMO:6818; Poster 532P.
Ratovomanana T, Nicolle R, Cohen R, et al. Prediction of response to immune checkpoint blockade in metastatic CRC with microsatellite instability: NIPICOL. Ann Oncol. 2023;34:703-713.
Gallois C, Sroussi M, André T, et al. Predictive models of recurrence from transcriptomic signatures in stage III colon cancer (PETACC-8 and IDEA France trials). J Clin Oncol. 2023;41(Suppl 16; abstr 3523). ASCO Annual Meeting, Abstract 3523; Poster 223.
Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Ann Oncol. 2022;33:628-637.
Rousseau B, Boukerma AK, Henriques J, et al. Impact of regorafenib and metabolite concentrations on OS in chemorefractory metastatic CRC: GERCOR TEXCAN study. Eur J Cancer. 2022;168:99-107.
Jary M, Liu WW, Yan D, et al. Immune microenvironment in mismatch-repair-proficient oligometastatic CRC exposed to chemotherapy: MIROX GERCOR cohort study. Mol Oncol. 2022;16:2260-2273.
Claire Gallois, Qian Shi, Meyers JP, et al. Prognostic impact of early treatment and oxaliplatin discontinuation in stage III colon cancer: ACCENT/IDEA pooled analysis. J Clin Oncol 41, 803-815 (2023). ASCO Gastrointestinal Cancers Symposium 2022, Abstract 11.
Cohen R, Meurisse A, Pudlarz T, et al. One-year duration of nivolumab plus ipilimumab in MSI/dMMR metastatic CRC: long-term follow-up of GERCOR NIPICOL phase II study. ASCO Gastrointestinal Cancers Symposium 2022, Abstract 13 & Poster C.
Chibaudel B, Dourthe LM, Andre T, et al. Multi-line therapy trial in unresectable RAS/BRAF wild-type metastatic CRC: phase III STRATEGIC-1 GERCOR-PRODIGE study. ESMO 2022, Abstract 5313.
Carola E, Chibaudel B, Boulahssass R, et al. Impact of age on treatment strategies in RAS/BRAF wild-type metastatic CRC: prespecified subgroup of STRATEGIC-1. ESMO 2022, Abstract 5523 & Poster 309P.
Taieb J, Taly V, Henriques J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: post hoc analysis of PRODIGE-GERCOR IDEA-France trial. Clin Cancer Res. 2021;27:5638-5646.
Fontana E, Meyers J, Sobrero A, et al. Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant therapy. J Clin Oncol. 2021;39:4009-4019.
Fontana E, Meyers J, Sobrero A, et al. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. J Clin Oncol 39, 4009-4019 (2021). ASCO Annual Meeting, Abstract 3517.
Basile D, Broudin C, Emile JF, et al. Tumor budding as an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy. Ann Oncol 32 (suppl_5): S530-S582. Mini oral session 388MO. ESMO Immuno-Oncology Congress 2021.
Pastor B, André T, Henriques J, et al. Monitoring circulating cfDNA as biomarker of response to regorafenib in metastatic CRC: TEXCAN study. Mol Oncol. 2021;15:2401-2411.
Ouali K, Turpin A, Neuzillet C, et al. Impact of IDEA results on clinical practice in France. Clin Colorectal Cancer. 2021;20:79-83.
Basile D, Gallois C, Puglisi F, et al. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi‑national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clin Res Hepatol Gastroenterol. 2021;45(3):101681. doi:10.1016/j.clinre.2021.101681.
Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer. Ann Oncol. 2020;31:921-929.
André T, Vernerey D, Im SA, et al. Bevacizumab as adjuvant treatment of colon cancer: updated AVANT results. Ann Oncol. 2020;31:246-256.
Chibaudel B, André T, Tournigand C, et al. Prognostic value of tumor location and KRAS: OPTIMOX3 DREAM analysis. Clin Colorectal Cancer. 2020;19:200-208.
Sobrero AF, Puccini A, Shi Q, et al. A new prognostic tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:182-188.
Delattre JF, Cohen R, Henriques J, et al. Prognostic value of tumor deposits in stage III colon cancer. J Clin Oncol. 2020;38:1702-1710.
Cohen R, Bennouna J, Meurisse A, et al. RECIST and iRECIST evaluation of nivolumab plus ipilimumab: NIPICOL study. J Immunother Cancer. 2020;8:e001499.
Chibaudel B, Henriques J, Rakez M, et al. Bevacizumab plus oxaliplatin and survival in stage II colon cancer: AVANT trial. JAMA Netw Open. 2020;3:e2020425.
Pagès F, Taieb J, Laurent-Puig P, et al. The consensus Immunoscore in phase III clinical trials. Oncoimmunology. 2020;9:1812221.
Makhloufi S, Turpin A, El Amrani M, et al. Fong’s score in metastatic CRC: MIROX trial analysis. Ann Surg Oncol. 2020;27:877-885.
Galon J, Hermitte F, Mlecnik B, et al. Immunoscore predicting recurrence and DFS in T4N0 stage II colon cancer. J Clin Oncol. 2020;38(suppl; abstr 4105). Abstract + oral (ASCO Virtual Scientific Program)
Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 in IDEA France cohort. J Clin Oncol. 2020;38(suppl 4; abstr 10). Abstract + oral (GI Cancers Symposium)
Sobrero AF, André T, Meyerhardt JA, et al. OS and DFS of 3 vs 6 months adjuvant therapy: IDEA collaboration. J Clin Oncol. 2020;38 (abstr 4004).
Pudlarz T, Montravers F, Garcia-Larnicol ML, et al. 18FDG-PET/CT in MSI metastatic CRC treated with ICIs. Ann Oncol. 2020;31(abstr 46P).
Cohen R, Bennouna J, Henriques J, et al. RECIST and iRECIST criteria in MSI/dMMR mCRC: NIPICOL study. J Clin Oncol. 2020;38. 2020 ASCO GI: Abstract 101, Poster Bd: E9.
Margalit O, Boursi B, Rakez M, et al. Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: analysis of MOSAIC and C‑07 trials. J Clin Oncol. 2020;38(4_suppl):118. ASCO 2020 Annual Meeting: Abstract 118, Poster Bd F4.
Di Fiore F, Bouché O, Lepage C, et al. Management of digestive cancers during the COVID-19 epidemic: French intergroup recommendations. Dig Liver Dis. 2020;52(6):597-603. doi:10.1016/j.dld.2020.03.031.
Hilmi M, Pellat A, Benoit O, et al. Nutrition and physical activity education in gastrointestinal oncology: a national survey. BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342.
Lièvre A, Turpin A, Ray-Coquard I, et al. Risk factors for COVID-19 severity and mortality among patients with solid tumors: French nationwide cohort (GCO-002 CACOVID-19). 2020.
Tougeron D, Michel P, Lièvre A, et al. Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Dig Liver Dis. 2021 Mar;53(3):306-308. doi: 10.1016/j.dld.2020.11.029.
TUMEURS NON COLORECTALES
Contenus 2026 à venir
Mehsood U, et al. Real-life insights into biliary tract cancers in France from the ACABi GERCOR PRONOBIL cohort. Dig Liver Dis. 2025 Apr;57(4):939. doi: 10.1016/j.dld.2024.12.012. Epub 2025 Jan 11. PMID: 39800587
Delaye M, et al. Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort. Dig Liver Dis. 2025 Jan;57(1):111-117. doi: 10.1016/j.dld.2024.06.032. Epub 2024 Jul 14. PMID: 39004550
Valery M, et al. Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi). Ther Adv Med Oncol. 2025 Oct 3;17:17588359251344013. doi: 10.1177/17588359251344013. PMID: 41049585
Adamus N, et al. First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort. JHEP Rep. 2024 Nov 20;7(2):101279. doi: 10.1016/j.jhepr.2024.101279. PMID: 39897613
Gros L, et al. Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial. Liver Int. 2025 Aug;45(8):e70196. doi: 10.1111/liv.70196. PMID: 40631456
Delaye M, et al. Durvalumab plus tremelimumab after platinum failure in biliary tract cancer: IMMUNOBIL PRODIGE 57. Annals of Oncology (2025) 36 (suppl_2): S233-S244. 10.1016/annonc/annonc1902. Mini Oral session: 80MO. 2025 ESMO Congress
Turpin A, et al. Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial. J Clin Oncol. 2025;43(Suppl 16): Abstract 4009. Doi: 10.1200/JCO.2025.43.16_suppl.4009 + Oral presentation. 2025 ASCO Annual Meeting
Turpin A, et al. Adjuvant capecitabine in resected BTC: PRODIGE83-ACABi-PRONOBIL. J Clin Oncol. 2025;43(Suppl 4):596. Abstract 596, Poster Bd: C22. 2025 ASCO GI
Adamus N, et al. Radiothérapie interne sélective associée à la chimiothérapie de première ligne dans le traitement du cholangiocarcinome intrahépatique : résultats de la cohorte française ACABi GERCOR PRONOBIL 2025. 2025 JFHOD. Communication oral : C081.
Lebeaud A, Antoun L, Paccard JR, et al. Management of biliary tract cancers in early-onset patients: ACABI GERCOR PRONOBIL cohort. Liver Int. 2024;44(8):1886–1899.
Kim S, Ghiringhelli F, de la Fouchardière C, et al. Atezolizumab plus modified DCF as first-line treatment for advanced anal cancer (SCARCE-PRODIGE 60). Lancet Oncol. 2024;25(4):518–528.
Hammel P, Smith D, Afchain P, et al. SUNLAND: sunitinib versus placebo plus lanreotide in advanced midgut neuroendocrine tumors. Ther Adv Med Oncol. 2024;16:17588359241290140.
Molina Beltran EE, Pereira S, Parent P, et al. Nutritional intervention with adapted physical activity in advanced pancreatic cancer (NUTAPACAP). Clin Nutr ESPEN. 2024;63:1298–1299 (LB079).
Cohen R, Raban N, Vernerey D, et al. Optimization of intraperitoneal chemotherapy: GERCOR CHIMOVIP study. J Clin Oncol. 2024;42(Suppl 16):5519.
Hammel P, Ben Abdelghani M, Roth G, et al. Maintenance olaparib or selumetinib plus durvalumab in mPDAC: MAZEPPA. J Clin Oncol. 2024;42(Suppl 3):673; Poster; Oral C121.
Molina Beltran EE, Gentilhomme L, Guillemin A, et al. Optimization of supportive care pathways in pancreatic and oesogastric cancer: POP-UP. JFHOD. 2024;P288.
Neuzillet C, Bouché O, Tournigand C, et L. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. J Natl Compr Canc Netw. 2023 Dec;21(12):1234-1242.e17. doi: 10.6004/jnccn.2023.7065.
André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab in localized dMMR gastric cancer. J Clin Oncol. 2023;41:255-265.
Kim S, Vendrely V, Saint A, et al. DCF versus doublet chemotherapy in advanced anal carcinoma: SCARCE. Exp Hematol Oncol. 2023;12:63.
Lebeaud A, Antoun L, Paccard J, et al. Early-onset biliary tract cancers: ACABI-PRONOBIL. Ann Oncol. 2023;34(Suppl 2): ESMO 2023 Meeting; Poster 120P.
Pudlarz T, Antoun L, Rousseau A, et al. Clinical and genomic features of young-onset biliary tract cancers: ACABI-PRONOBIL. Ann Oncol. 2023;34(Suppl 2), ESMO 2023 Meeting; Abstract 112P.
Borg C, Vendrely V, Saint A, et al. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study SCARCE. Ann Oncol. 2023;34: ESMO 2023 Meeting; Abstract 651P.
Rousseau B, Falcoz A, Toullec C, et al. Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study. J Clin Oncol 41, 2023 (suppl 4; abstr 700). 2023 GI Symposium, Abstract 700, Poster BD: K7
Neuzillet C, Bouché O, Tournigand C, et al. Adapted physical activity in advanced pancreatic cancer: APACaP. JFHOD. 2023. Communication oral: C.071
Delaye M, Assenat E, Dahan L, et al. Durvalumab plus tremelimumab in advanced biliary tract carcinoma: IMMUNOBIL. JFHOD. 2023. Communication oral: C.020
Charton E, Falcoz A, François E, et al. %TTD and %TUDD SAS macros for PRO analysis in oncology. Comput Methods Programs Biomed. 2022;214:106537.
Evrard D, Dumont C, Gatineau M, et al. mTOR inhibition and chemotherapy in head and neck cancer: CAPRA study. Cancers. 2022;14:4509.
Neuzillet C, Bouché O, Tournigand C, et al. Adapted physical activity in advanced pancreatic cancer: APACaP trial. J Clin Oncol. 2022;40(Suppl 16):4007. 2022 ASCO Annual Meeting, Abstract 4007; Oral presentation.
Delaye M, Assenat E, Dahan E, et al. Durvalumab plus tremelimumab after platinum failure in biliary tract carcinoma: IMMUNOBIL. J Clin Oncol. 2022;40:4108. 2022 ASCO Annual Meeting, Abstract 4108; Poster 95.
André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab in MSI/dMMR oesophagogastric adenocarcinoma: NEONIPIGA. J Clin Oncol. 2022;40(Suppl 4):244. 2022 ASCO Gastrointestinal Cancers Symposium, Abstract 244; Poster BD:E2; Oral presentation.
Kim S, Ghiringhelli F, de La Fouchardière C, et al. Atezolizumab plus modified DCF in anal cancer: SCARCE-PRODIGE 60. J Clin Oncol. 2022;40:3508. 2022 ASCO Annual Meeting, Abstract 3508; Oral presentation.
Hilmi M, Mitry E, Turpin A/E, et al. Maintenance OSE2101 ± nivolumab or FOLFIRI after FOLFIRINOX: TEDOPAM. J Clin Oncol. 2022;40:4148. 2022 ASCO Annual Meeting, Abstract 4148; Poster BD:133.
Bachet JB, Bouché O, Jary M, et al. Trifluridine/tipiracil with G-CSF support: LONGBOARD. JFHOD. 2022;Poster P.051.
French intergroup (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Desmoid tumors located in the abdomen or associated with adenomatous polyposis: clinical practice guidelines for diagnosis, treatment, and follow-up. Dig Liver Dis. 2022;54(6):737–746. doi:10.1016/j.dld.2022.03.004
Boilève A, Hilmi M, Gougis P, et al. Triplet durvalumab, tremelimumab and paclitaxel in biliary tract carcinoma: IMMUNOBIL PRODIGE 57. Eur J Cancer. 2021;143:55-63.
Giraud P, Racadot S, Vernerey D, et al. Radiation therapy quality and outcomes in LAP07 trial. Int J Radiat Oncol Biol Phys. 2021;110:993-1002.
Schernberg A, Vernerey D, Goldstein D, et al. Neutrophil count and tumor control after chemoradiotherapy in LAPC. Int J Radiat Oncol Biol Phys. 2021;110:1022-1031.
Hilmi M, Hautefeuille V, Lambert A, et al. A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY). Ann Oncol. 2021;32(Suppl 5). ASCO Gastrointestinal Cancers Symposium 2021.
Cohen R, Pudlarz T, Garcia-Larnicol ML, et al. Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire: l’essai de phase II GERCOR NEONIPIGA. Bull Cancer. 2020;107:438-446. doi:10.1016/j.bulcan.2019.11.016.
Kim S, Buecher B, André T, et al. Atezolizumab plus modified DCF versus mDCF in advanced anal squamous cell carcinoma: SCARCE trial. BMC Cancer. 2020;20:352. doi:10.1186/s12885-020-06841-1.
Aparicio T, Henriques J, Manfredi S, et al. Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. Int J Cancer. 2020;147(4):967-977. doi:10.1002/ijc.32860.
Boilève A, Hilmi M, Gougis P, et al. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the IMMUNOBIL PRODIGE 57 phase II trial. Eur J Cancer. 2020;143:55-63. doi:10.1016/j.ejca.2020.10.027.
de Mestier L, Lepage C, Baudin E, et al. Digestive neuroendocrine neoplasms: French intergroup clinical practice guidelines. Dig Liver Dis. 2020;52(5):473-492. doi:10.1016/j.dld.2020.02.011.
Vernerey D, Meurisse A, Hammel P, et al. FOLFIRINOX de-escalation in advanced pancreatic cancer: real-life study. J Clin Oncol. 2020 (abstr 4639).
Gérer le consentement
Pour offrir les meilleures expériences, nous utilisons des technologies telles que les cookies pour stocker et/ou accéder aux informations des appareils. Le fait de consentir à ces technologies nous permettra de traiter des données telles que le comportement de navigation ou les ID uniques sur ce site. Le fait de ne pas consentir ou de retirer son consentement peut avoir un effet négatif sur certaines caractéristiques et fonctions.
Fonctionnel
Toujours activé
L’accès ou le stockage technique est strictement nécessaire dans la finalité d’intérêt légitime de permettre l’utilisation d’un service spécifique explicitement demandé par l’abonné ou l’utilisateur, ou dans le seul but d’effectuer la transmission d’une communication sur un réseau de communications électroniques.
Préférences
L’accès ou le stockage technique est nécessaire dans la finalité d’intérêt légitime de stocker des préférences qui ne sont pas demandées par l’abonné ou l’internaute.
Statistiques
Le stockage ou l’accès technique qui est utilisé exclusivement à des fins statistiques.Le stockage ou l’accès technique qui est utilisé exclusivement dans des finalités statistiques anonymes. En l’absence d’une assignation à comparaître, d’une conformité volontaire de la part de votre fournisseur d’accès à internet ou d’enregistrements supplémentaires provenant d’une tierce partie, les informations stockées ou extraites à cette seule fin ne peuvent généralement pas être utilisées pour vous identifier.
Marketing
L’accès ou le stockage technique est nécessaire pour créer des profils d’internautes afin d’envoyer des publicités, ou pour suivre l’utilisateur sur un site web ou sur plusieurs sites web ayant des finalités marketing similaires.
